Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Depressants01:28

Depressants

Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mental and somatic multimorbidity among individuals with alcohol use disorder: A sex-stratified registry study.

Drug and alcohol dependence·2026
Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Patterns of substance-induced psychosis during the COVID-19 pandemic: a national registry study of specialist healthcare contacts.

Social psychiatry and psychiatric epidemiology·2026
Same author

FDA Approves Reduced Drinking Endpoints for Alcohol Trials: A New Road for Alcohol Treatment?

European addiction research·2026
Same author

Socioeconomic Position and Somatic Comorbidity in Mental Disorders.

Acta psychiatrica Scandinavica·2026
Same author

The Interaction Between Mental Distress and Opioid Maintenance Treatment Impacts Levels of Circulating Cytokines.

Addiction biology·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Correction: Management of acute epistaxis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

More systematic follow-up after childbirth.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

[Baclofen for alcohol addiction].

Arne Helland1, Jørgen G Bramness

  • 1Avdeling for klinisk farmakologi, St. Olavs hospital, Norway. arne.helland@legemidler.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 4, 2011
PubMed
Summary
This summary is machine-generated.

Baclofen is not recommended for alcohol withdrawal due to weak evidence. It may be considered for relapse prevention if other treatments fail, but high-dose use for craving lacks sufficient proof.

More Related Videos

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Related Experiment Videos

Last Updated: May 27, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Neurology

Context:

  • Baclofen is FDA-approved for muscle spasms and spasticity.
  • Emerging research explores its efficacy in managing alcohol use disorder (AUD).
  • Current evidence for baclofen in AUD treatment is under review.

Purpose:

  • To evaluate the current evidence for baclofen in treating alcohol withdrawal symptoms.
  • To assess baclofen's effectiveness as an abstinence-promoting agent in alcohol-dependent individuals.
  • To determine the suitability of baclofen for managing alcohol craving and relapse.

Summary:

  • Evidence supporting baclofen for alcohol withdrawal is insufficient; established treatments like benzodiazepines are preferred.
  • Baclofen may be a consideration for preventing relapse in alcohol dependence when standard therapies (disulfiram, acamprosate) are ineffective.
  • High-dose baclofen for suppressing alcohol craving lacks robust evidence, despite anecdotal reports. Further clinical trials are ongoing.

Impact:

  • This review clarifies the current limitations and potential roles of baclofen in alcohol use disorder management.
  • It guides clinicians on appropriate use, emphasizing evidence-based treatments for alcohol withdrawal.
  • Highlights the need for further research to establish baclofen's definitive role in AUD treatment, particularly for relapse prevention and craving suppression.